Nautilus Biotechnology, a Seattle-based biotech startup led by Isilon co-founder Sujal Patel, is the latest company to go public using a special purpose acquisition company, or SPAC. The deal, announced Monday morning, will inject approximately $350 million into Nautilus, which is developing a next-generation platform to analyze the human proteome, or the body’s full set of proteins. It values the company at $900 million. The company plans to raise $150 million as part of a merger with Arya Sciences Acquisition Corp III, a publicly-traded SPAC sponsored by existing Nautilus investor Perceptive Advisors.